3 Future Stars in Big Pharma's Best Pipeline

Health care leader Johnson & Johnson's (NYSE: JNJ  ) drug business is only one part of this company's diversified medical portfolio, but it has recently emerged as J&J's biggest division by sales. Drug sales jumped almost 10% for Johnson & Johnson in the third quarter alone, surpassing medical devices in total revenues. That was thanks to the gains made by old, reliable drugs like immunology blockbuster Remicade, as well as up-and-coming drugs that are lighting up investors' hopes for the future.

But Johnson & Johnson's not a company to sit on its laurels. Its pipeline is packed with punch to continue its pharmaceutical success long into the future. So, which drugs under development do investors need to keep an eye on?

In the video below, Fool contributor Dan Carroll highlights three key drugs in Johnson & Johnson's drug pipeline that could emerge as major players in this health care giant's future -- and what they could mean for this stock's long-term future.

Is Johnson & Johnson the best dividend stock for your money?
Johnson & Johnson's steady, reliable performance over the years has made this stock one tried-and-true blue-chip pick that dividend investors can count on. However, the best income investors understand the power of a portfolio's diversity. Which are the best dividend stocks around the market that should catch your eye? Our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2709838, ~/Articles/ArticleHandler.aspx, 9/26/2016 10:04:56 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 48 minutes ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:01 PM
JNJ $117.78 Down -1.03 -0.87%
Johnson and Johnso… CAPS Rating: *****
AMGN $173.53 Down -1.27 -0.73%
Amgen CAPS Rating: ****
CELG $106.31 Down -3.12 -2.85%
Celgene CAPS Rating: *****
PCYC.DL $0.00 Down +0.00 +0.00%